Oncology competition spotlights non-medical solutions that can close patient-support gap
Pharma has struggled to align patient services with the needs of disease communities. Open innovation represents one approach towards closing the gap.
Pharma has struggled to align patient services with the needs of disease communities. Open innovation represents one approach towards closing the gap.
Oncology is moving toward a future in which treatments are genetically matched to patients’ tumors. But we won’t get there without generating a lot more awareness about molecular diagnostics, says Caris’ commercial chief.
Q1 earnings from Bristol-Myers Squibb, Bayer, Johnson & Johnson, AbbVie and Novartis showed strong growth by oncology drugs.
Maximize your engagement with specialty providers and gain valuable insights on their perspectives through Cardinal Health’s Specialty Summits.
AstraZeneca’s lupus drug fails to meet goals; FDA expands investigation into heart drugs; Lilly names new head of Oncology.
Opdivo’s commercial potential will likely take a hit in the wake of new Keytruda data, but the impact may depend on the ability of BMS to market the message that its I-O/I-O combo allows patients to delay chemo.
As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.
Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.
Amazon, Berkshire Hathaway, and JPMorgan team up to form a healthcare company; Takeda’s Zika vaccine receives FDA fast-track status
FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW